Please login to the form below

Not currently logged in
Email:
Password:

Rybelsus

This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity scores CV reduction indication in the US

Lilly’s Trulicity scores CV reduction indication in the US

Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn

Latest news

  • New drugs drive Novo Nordisk despite insulin price pressures New drugs drive Novo Nordisk despite insulin price pressures

    Novo also reported sales of DKK50m for its recently launched oral semaglutide product  Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and

  • Givlaari, Rybelsus lead crowded CHMP recommendations Givlaari, Rybelsus lead crowded CHMP recommendations

    Joining Givlaari with a positive recommendation was  Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved

  • Novo Nordisk gets MACE prevention claim for Ozempic in US Novo Nordisk gets MACE prevention claim for Ozempic in US

    Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus – SOUL – that is due to generate data in 2024. ... Some market predictors think Rybelsus could go even higher if the SOUL data is competitive.

  • Novo bolstered by new diabetes, obesity products Novo bolstered by new diabetes, obesity products

    Also helping to bolster its sales and growth is new oral semaglutide drug Rybelsus, which received approval from the FDA in the US  recently. ... Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk. "During the third quarter of 2019, we have

  • Novo Nordisk gets FDA okay for new diabetes hope Novo Nordisk gets FDA okay for new diabetes hope

    product. The US regulator has approved the Danish drugmaker’s  oral formulation of semaglutide under the Rybelsus brand name, extending its range of GLP-1 agonist drugs that include once-weekly ... Rybelsus will be launched in the US in the fourth

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics